Breast Cancer Clinical Trials & Research at Providence Medical Group
In the U.S., breast cancer is the second most common cancer in women after
skin cancer. It can occur in both men and women. The most common type
of breast cancer is ductal carcinoma, which begins in the cells of the
ducts. Breast cancer can also begin in the cells of the lobules and in
other tissues in the breast. Invasive breast cancer is breast cancer that
has spread from where it began in the ducts or lobules to surrounding tissue.
Providence Medical Group is currently enrolling patients for the following
breast cancer clinical trials:
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast
Cancer (MA.39 TAILOR RT)
Treatment agent: Radiotherapy
Physician:
Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / Canadian Cancer Trials Group
Location: Providence Queen of the Valley Medical Center, Napa, CA
Sermonix SMX-22-002 ELAINE 3
Treatment agent: Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib
Physician:
Jarrod Holmes, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant
Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2-
Breast Cancer With an ESR1 Mutation - Full Text View - ClinicalTrials.gov
Sponsor: Sermonix Pharmaceuticals Inc.
Location: Providence Cancer Center, Santa Rosa, CA
Study for participants with Stave IV advanced/ metastatic Hormone Receptor
positive, HER2 negative breast cancer (Capitello 292)
Treatment agent: Capiversitib + CDK4/6 inhibitor + Fulvestrant
Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study Details | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic
HR+/HER2- Breast Cancer (CAPItello-292) | ClinicalTrials.gov
Sponsor: Capitello
Location: Providence Cancer Center, Santa Rosa, CA
Study for participants with PD-L1 positive locally recurrent, inoperable,
or metastatic triple negative breast cancer (Tropion Breast 05) Treatment
agent: Dato-DXd With or Without Durvalumab Compared With Investigator's
Choice of Chemotherapy in Combination With Pembrolizumab
Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Phase III Study of Dato-DXd With or Without Durvalumab
Compared With Investigator's Choice of Chemotherapy in Combination
With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable
or Metastatic Triple-negative Breast Cancer | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
Neo-adjuvant and adjuvant ( treatment study for participants with triple
negative or hormone receptor low or HER2 negative breast cancer (Tropion
Breast 04)
Treatment agent: Dato-DXd and Durvalumab
Physician: Dr Jarrod Holmes
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab
for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative
Breast Cancer | ClinicalTrials.gov
Sponsor: Astra Zeneca
Location: Providence Cancer Center, Santa Rosa, CA
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the
Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects
with Solid Tumors or Lymphoma
Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression
Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment
to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual
Disease (RD), A Double-Blinded, Phase III Randomized Trial of TDM1 and
Placebo Compared with T-DM1 and Tucatinib